Revenue was 269.2 billion yen (Year-over-Year +9%), adjusted operating margin 17.8%, adjusted EPS 32 yen. The first half demonstrates progress against the FY2027\u2013FY2029 plan, with continued growth in GIS and urology\/respiratory segments. Full-year outlook has been revised upward. Impact from FDA corrective actions and import warnings is viewed as limited. The acquisition of BioProtect and other transactions affected the financials.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7733-20261110-02.pdf","jir_short_summary":"Revenue was 269.2 billion yen (Year-over-Year +9%), adjusted operating margin 17.8%, adjusted EPS 32 yen. The first half demonstrates progress against the FY2027\u2013FY2029 plan, with continued growth in GIS and urology\/respiratory segments. Full-year outlook has been revised upward. Impact from FDA corrective actions and import warnings is viewed as limited. The acquisition of BioProtect and other transactions affected the financials.","jir_summary":"### Performance Overview\nIn Q2, priority initiatives across finance, operations and strategy progressed smoothly. Strong growth in GIS and continued double-digit growth in urology and respiratory segments drove overall revenue increases year-on-year. The first-half targets under the FY2027\u2013FY2029 plan were steadily achieved, leading to an upward revision of the full-year lower bound. FDA-related corrective actions are ongoing, but are not expected to have a material impact on consolidated results for FY2027. Integration of BioProtect and expansion of the new portfolio are also underway.\n\n### Outlook and Key Drivers\nFirst-half growth was supported by strong execution of GIS in North America, Europe and APAC, with product lines in urology and respiratory remaining robust. Full-year guidance is revenue 1,064.5 hundred million yen to 1,076.0 hundred million yen, adjusted EPS 111 yen to 119 yen (lower bound TBD), and an annual dividend of 30 yen is planned. While continuing responses to FDA import warnings and quality corrective actions, capital strategy is being advanced with consideration of the BioProtect acquisition impact.","jir_financial_highlights":"Revenue: 269.2 hundred million yen (Year-over-Year +9%)\nAdjusted Operating Margin: 17.8% (Year-over-Year +2.8pp)\nAdjusted EPS: 32 yen (Year-over-Year +38%)\nAdjusted Free Cash Flow: 23.6 hundred million yen (Year-over-Year +198%)","jir_category":"","jir_hashtags":"#Olympus, #Earnings, #GISGrowth, #QualityReform","jir_key_figures":"Revenue: 269.2 hundred million yen (Year-over-Year +9%)\nAdjusted EPS: 32 yen (Year-over-Year +38%)\nAdjusted Operating Margin: 17.8% (Year-over-Year +2.8pp)","jir_meta_title":"Olympus Corporation Q2 Financial Summary | Revenue 269.2 billion yen \u00b7 EPS 32 yen \u00b7 Margin Improvement","jir_meta_description":"Olympus Corporation Q2 consolidated results for fiscal year ending March 2027: revenue 269.2 billion yen (Year-over-Year +9%), adjusted EPS 32 yen, adjusted operating margin 17.8%. Continued growth in GIS, urology and respiratory segments; full-year outlook revised upward. Overview of FDA corrective actions included.","jir_og_title":"Key Points from Olympus Corporation Q2 Results | Revenue 269.2 billion yen \u00b7 EPS 32 yen \u00b7 Margin Improvement","jir_og_description":"Olympus Corporation Q2 consolidated results for FY2027. Growth sustained around GIS, full-year outlook improved. Summary of FDA response progress and impact of the BioProtect acquisition.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2478,2692]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[295,389]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Adjusted Operating Margin\\\",\\\"data\\\":[15.1,17.8]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Endoscopy\\\",\\\"Endoscopy Devices\\\",\\\"SIS\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY27\\\",\\\"data\\\":[1845,846,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26\\\",\\\"FY27\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue Forecast\\\",\\\"data\\\":[? ,105?]}]},\\\"options\\\":{}}\"}]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147280","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n